InsiderTrades.com logo
Joan Nickerson net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Joan Nickerson Biography and Net Worth

Senior Vice President, Human Resources and Facilities of Verve Therapeutics

Joan Nickerson is senior vice president, human resources and facilities at Verve Therapeutics with over 25 years’ experience in human resources. Prior to joining Verve, she led the HR functions at Dyax Corp., until it was acquired by Shire, and most recently at Sarepta Therapeutics. Ms. Nickerson holds a BBA from the University of Massachusetts and an MBA from Simmons College in Boston.

What is Joan Nickerson's net worth?

The estimated net worth of Joan Nickerson is at least $193.88 thousand as of April 2nd, 2025. Mr. Nickerson owns 17,420 shares of Verve Therapeutics stock worth more than $193,885 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Nickerson may own. Learn More about Joan Nickerson's net worth.

How old is Joan Nickerson?

Mr. Nickerson is currently 55 years old. There are 5 older executives and no younger executives at Verve Therapeutics. The oldest executive at Verve Therapeutics is Dr. Barry S. Ticho FACC, M.D., Ph.D., Co-Founder, who is 63 years old. Learn More on Joan Nickerson's age.

How do I contact Joan Nickerson?

The corporate mailing address for Mr. Nickerson and other Verve Therapeutics executives is , , . Verve Therapeutics can also be reached via phone at 617-603-0070 and via email at [email protected]. Learn More on Joan Nickerson's contact information.

Has Joan Nickerson been buying or selling shares of Verve Therapeutics?

Joan Nickerson has not been actively trading shares of Verve Therapeutics during the last ninety days. Most recently, Joan Nickerson sold 2,777 shares of the business's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $4.15, for a transaction totalling $11,524.55. Following the completion of the sale, the insider now directly owns 17,420 shares of the company's stock, valued at $72,293. Learn More on Joan Nickerson's trading history.

Who are Verve Therapeutics' active insiders?

Verve Therapeutics' insider roster includes Burt Adelman (Director), Andrew Ashe (Insider), Andrew Bellinger (Insider), Allison Dorval (CFO), Sekar Kathiresan (CEO), and Joan Nickerson (Senior Vice President, Human Resources and Facilities). Learn More on Verve Therapeutics' active insiders.

Are insiders buying or selling shares of Verve Therapeutics?

In the last twelve months, insiders at the sold shares 2 times. They sold a total of 6,127 shares worth more than $25,427.05. The most recent insider tranaction occured on April, 2nd when insider Joan Nickerson sold 2,777 shares worth more than $11,524.55. Insiders at Verve Therapeutics own 19.3% of the company. Learn More about insider trades at Verve Therapeutics.

Information on this page was last updated on 4/2/2025.

Joan Nickerson Insider Trading History at Verve Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2025Sell2,777$4.15$11,524.5517,420View SEC Filing Icon  
4/2/2024Sell1,514$8.24$12,475.368,659View SEC Filing Icon  
See Full Table

Joan Nickerson Buying and Selling Activity at Verve Therapeutics

This chart shows Joan Nickerson's buying and selling at Verve Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verve Therapeutics Company Overview

Verve Therapeutics logo
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $11.13
Low: $11.13
High: $11.13

50 Day Range

MA: $11.13
Low: $10.91
High: $11.38

2 Week Range

Now: $11.13
Low: $2.86
High: $11.40

Volume

N/A

Average Volume

3,941,096 shs

Market Capitalization

$992.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.23